Ontozry Approved In EU For Refractory Epilepsy Treatment, Clinical Data Demonstrate Significant Efficacy
The European Medicines Agency (EMA) recently approved Ontozry (cenobamato) for the treatment of refractory focal…
News
Ogsiveo (Nirogacestat) Emerges As First Targeted Therapy For Desmoid Tumors Offering New Hope For Patients
April 12, 2025 — In a landmark advancement for rare cancer treatment, Ogsiveo® (nirogacestat) has solidified its position…
FDA-Approved Ojjaara (Momelotinib) Emerges As Breakthrough Treatment For Myelofibrosis With Anemia
April 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) as the first…
Rytelo (Imestat): First Inhibitor Offers New Hope For Patients With Transfusion-Dependent MDS
On June 6, 2024, the U.S. Food and Drug Administration (FDA) granted approval for Rytelo™…
Qelbree: A Drug That Brings New Hope For Specific Needs
Recently, Qelbree has attracted a lot of attention in the pharmaceutical field.Qelbree focuses on specific…
Revuforj: New Hope For Patients With Acute Leukaemia
On 15 November 2024, the US Food and Drug Administration (FDA) approved a new drug…
Novartis Zolgensma Gene Therapy Has Significant Long-Term
Zolgensma (onasemnogene abeparvovec), Novartis’ gene therapy for spinal muscular atrophy (SMA), recently announced landmark long-term…
Rezolsta For Adolescent HIV Patients To Further Optimise Antiretroviral Regimens
The European Commission (EC) has approved an expansion of the indication for the anti-HIV combination…
Rylaze Receives FDA Approval: A Key Treatment Option For Patients With Acute Lymphoblastic Leukaemia
FDA Approval Of Rylaze Fills Asparaginase Shortage Gap, Offers New Hope For ALL/LBL Patients In…
Ravicti: Urea Cycle Disorders—Development, Clinical Results, Market Growth, and Patient Impact
Amidst the continuous progress in the field of medicine, Ravicti (glycerol phenylbutyrate), an innovative drug,…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights